EUVIMEDEUVIMED entdecken
Open Access

USH2A mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer

Dexin Yang, Yuqin Feng, Haohua Lu, Kelie Chen, Jinming Xu, Peiwei Li, Tianru Wang, Dajing Xia, Yihua Wu

Journal of Zhejiang University-SCIENCE B · 2023

DOI: 10.1631/jzus.b2200292 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Zhejiang University-SCIENCE B, 2023. Verfasst von Dexin Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Toxicology of School of Public Health, and Department of Gynecologic Oncology of Women's Hospital, School of Medicine, Zhejiang Univers…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Extracellular Matrix Proteins, Immune Checkpoint Inhibitors, Lung Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: the National Natural Science Foundation of China, the Zhejiang Provincial Natural Science Foundation of China, the Fundamental Research Funds for the Central Universities, and the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungExtracellular Matrix ProteinsImmune Checkpoint InhibitorsLung NeoplasmsHumansErbB ReceptorsMutationProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)Treatment Outcome

Stichwörter der Autor:innen

Epidermal growth factor receptor (EGFR) mutationImmune checkpoint inhibitor (ICI)Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation combined w…Lung cancerUsher syndrome type-2A (USH2A) missense mutation

Substanzen

ErbB ReceptorsExtracellular Matrix ProteinsImmune Checkpoint InhibitorsProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)USH2A protein, human

Autor:innen und Institutionen

  • Department of Toxicology of School of Public Health, and Department of Gynecologic Oncology of Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China.
  • Graduate School of Biomedical Sciences, University of Texas MD Anderson Cancer Center and UTHealth, Houston; Department of Biochemistry and Molecular Biology, McGovern Medical School, University of Texas Health Science…
  • Department of Thoracic Surgery, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
  • Department of Gastroenterology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China.
  • Epidemiology Stream, Dalla Lana School of Public Health, University of Toronto, Toronto, M5S 2E8, Canada.
  • Department of Toxicology of School of Public Health, and Department of Gynecologic Oncology of Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China. dxia@zju.edu.cn.

Förderung

  • the National Natural Science Foundation of China
  • the Zhejiang Provincial Natural Science Foundation of China
  • the Fundamental Research Funds for the Central Universities, and the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS)

Zitieren

APA

Yang, D., Feng, Y., Lu, H., Chen, K., Xu, J., Li, P., Wang, T., Xia, D., & Wu, Y. (2023). USH2A mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer. Journal of Zhejiang University-SCIENCE B. https://doi.org/10.1631/jzus.b2200292

Vancouver

Yang D, Feng Y, Lu H, Chen K, Xu J, Li P, et al. USH2A mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer. Journal of Zhejiang University-SCIENCE B. 2023. doi:10.1631/jzus.b2200292

BibTeX
@article{Yang2023,
  author = {Yang, Dexin and Feng, Yuqin and Lu, Haohua and Chen, Kelie and Xu, Jinming and Li, Peiwei and Wang, Tianru and Xia, Dajing and Wu, Yihua},
  title = {USH2A mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer},
  journal = {Journal of Zhejiang University-SCIENCE B},
  year = {2023},
  doi = {10.1631/jzus.b2200292}
}
Kostenlos starten →